The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.
 
Adil Daud
Stock and Other Ownership Interests - Neuvogen; Trex bio
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Genoptix; GlaxoSmithKline; Merck; Oncosec; Pfizer
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering Plough (Inst); Novartis; oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Vamsidhar Velcheti
Honoraria - Galvanize Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Novocure; Picture Health; Regeneron; Taiho Oncology; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Katherine M. Bever
Employment - AstraZeneca (I); Personal Genome Diagnostics (I); Qiagen (I); SOPHiA Genetics (I)
Stock and Other Ownership Interests - SOPHiA Genetics (I)
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Warren Allen Chow
Other Relationship - Advenchen Laboratories; InhibRx
 
Costantine Albany
Travel, Accommodations, Expenses - Sanofi
 
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Nikang Therapeutics (Inst); Novartis (Inst); Novartis (Inst); US Oncology (Inst)
 
Katy K. Tsai
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ABM (Inst); AstraZeneca (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Oncosec (Inst); OnKure (Inst); Pfizer (Inst); Replimune (Inst)
 
Michael Jon Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jieyi Wang
Employment - Lyvgen Biopharma
Leadership - Lyvgen Biopharma
Stock and Other Ownership Interests - Lyvgen Biopharma
Patents, Royalties, Other Intellectual Property - patents at Abbott, AbbVie, and Lyvgen
Travel, Accommodations, Expenses - Lyvgen Biopharma
 
C. Hubert Chan
Employment - Lyvgen Biopharma
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)